Bio Techne Corp Stock Current Valuation

TECH Stock

USD 75.01 0.24 0.32%

Valuation analysis of Bio Techne Corp helps investors to measure Bio Techne's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The Bio Techne's current Enterprise Value is estimated to increase to about 2.3 B, while Enterprise Value Over EBITDA is projected to decrease to 17.21. Fundamental drivers impacting Bio Techne's valuation include:

Price Book

5.7525

Enterprise Value

12.2 B

Enterprise Value Ebitda

39.6227

Price Sales

10.173

Forward PE

39.8406

Fairly Valued

Today

75.01

Please note that Bio Techne's price fluctuation is very steady at this time. Calculation of the real value of Bio Techne Corp is based on 3 months time horizon. Increasing Bio Techne's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.

Buy or Sell Advice Valuation Matrix

Since Bio Techne is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bio Stock. However, Bio Techne's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.

Historical

Market 75.01

Real 73.79

Target 85.26

Hype 75.01

Naive 68.84

The intrinsic value of Bio Techne's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Bio Techne's stock price.

71.58

Downside

73.78

Real Value

Target Odds

Above Odds

Below Odds

75.99

Upside

Estimating the potential upside or downside of Bio Techne Corp helps investors to forecast how Bio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio Techne more accurately as focusing exclusively on Bio Techne's fundamentals will not take into account other important factors:

Earnings

Estimates (0)

Low	Projected	High
0.51	0.51	0.52

Details

Hype

Prediction

Low	Estimated	High
72.80	75.01	77.22

Details

Potential

Annual Dividend

Low	Forecasted	High
0.21	0.21	0.21

Details

15 Analysts

Consensus

Low	Target Price	High
77.59	85.26	94.64

Details

Bio Techne Corp Company Current Valuation Analysis

Bio Techne's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Bio Techne Current Valuation

12.17 B

Most of Bio Techne's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Techne Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Bio Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Bio Techne is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Current Valuation. Since Bio Techne's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Techne's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Techne's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Good Will	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.76	0.98	0.98	0.91	0.9	0.87	0.51	0.9	-0.46	0.8	0.81	0.76	0.98	0.92	0.14	0.94	0.72	0.69	-0.03	0.78	0.22	0.9	0.77
Total Stockholder Equity	0.98		0.65	0.99	0.98	0.82	0.93	0.86	0.39	0.82	-0.46	0.85	0.7	0.73	0.94	0.9	0.29	0.96	0.61	0.68	-0.07	0.67	0.24	0.89	0.83
Net Debt	0.76	0.65		0.68	0.73	0.92	0.44	0.56	0.75	0.89	-0.42	0.47	0.94	0.55	0.84	0.79	-0.35	0.64	0.78	0.56	0.1	0.9	0.22	0.67	0.46
Retained Earnings	0.98	0.99	0.68		0.96	0.86	0.93	0.82	0.5	0.86	-0.41	0.8	0.74	0.73	0.95	0.87	0.18	0.91	0.66	0.6	-0.02	0.7	0.24	0.85	0.76
Net Receivables	0.98	0.98	0.73	0.96		0.86	0.87	0.82	0.45	0.84	-0.55	0.86	0.75	0.67	0.96	0.95	0.24	0.96	0.67	0.66	-0.03	0.72	0.28	0.88	0.84
Total Liab	0.91	0.82	0.92	0.86	0.86		0.71	0.77	0.72	0.98	-0.42	0.56	0.97	0.74	0.95	0.86	-0.25	0.78	0.88	0.63	0.07	0.93	0.13	0.79	0.53
Total Current Assets	0.9	0.93	0.44	0.93	0.87	0.71		0.83	0.31	0.69	-0.22	0.75	0.59	0.71	0.81	0.72	0.31	0.86	0.55	0.64	-0.05	0.59	0.18	0.82	0.71
Short Term Debt	0.87	0.86	0.56	0.82	0.82	0.77	0.83		0.24	0.78	-0.33	0.57	0.62	0.87	0.84	0.85	0.16	0.9	0.61	0.8	-0.13	0.6	-0.07	0.86	0.55
Accounts Payable	0.51	0.39	0.75	0.5	0.45	0.72	0.31	0.24		0.74	-0.18	0.11	0.8	0.36	0.6	0.41	-0.61	0.25	0.74	0.09	0.34	0.76	0.32	0.33	0.08
Intangible Assets	0.9	0.82	0.89	0.86	0.84	0.98	0.69	0.78	0.74		-0.45	0.51	0.93	0.77	0.95	0.85	-0.27	0.76	0.85	0.56	0.08	0.88	0.07	0.76	0.48
Short Term Investments	-0.46	-0.46	-0.42	-0.41	-0.55	-0.42	-0.22	-0.33	-0.18	-0.45		-0.57	-0.38	-0.21	-0.54	-0.64	-0.2	-0.53	-0.36	-0.17	0.01	-0.33	-0.19	-0.42	-0.59
Common Stock	0.8	0.85	0.47	0.8	0.86	0.56	0.75	0.57	0.11	0.51	-0.57		0.47	0.36	0.73	0.77	0.58	0.85	0.32	0.56	-0.13	0.46	0.44	0.76	1.0
Long Term Debt	0.81	0.7	0.94	0.74	0.75	0.97	0.59	0.62	0.8	0.93	-0.38	0.47		0.6	0.86	0.75	-0.38	0.66	0.86	0.56	0.18	0.98	0.19	0.7	0.44
Property Plant Equipment	0.76	0.73	0.55	0.73	0.67	0.74	0.71	0.87	0.36	0.77	-0.21	0.36	0.6		0.75	0.71	-0.03	0.72	0.71	0.61	-0.08	0.61	-0.21	0.81	0.33
Good Will	0.98	0.94	0.84	0.95	0.96	0.95	0.81	0.84	0.6	0.95	-0.54	0.73	0.86	0.75		0.95	0.01	0.91	0.77	0.65	0.01	0.82	0.22	0.87	0.71
Current Deferred Revenue	0.92	0.9	0.79	0.87	0.95	0.86	0.72	0.85	0.41	0.85	-0.64	0.77	0.75	0.71	0.95		0.17	0.95	0.68	0.7	-0.06	0.7	0.19	0.89	0.77
Net Tangible Assets	0.14	0.29	-0.35	0.18	0.24	-0.25	0.31	0.16	-0.61	-0.27	-0.2	0.58	-0.38	-0.03	0.01	0.17		0.37	-0.33	0.23	-0.29	-0.36	0.16	0.27	0.6
Capital Surpluse	0.94	0.96	0.64	0.91	0.96	0.78	0.86	0.9	0.25	0.76	-0.53	0.85	0.66	0.72	0.91	0.95	0.37		0.58	0.79	-0.13	0.63	0.17	0.94	0.84
Deferred Long Term Liab	0.72	0.61	0.78	0.66	0.67	0.88	0.55	0.61	0.74	0.85	-0.36	0.32	0.86	0.71	0.77	0.68	-0.33	0.58		0.41	0.14	0.86	0.01	0.65	0.3
Long Term Investments	0.69	0.68	0.56	0.6	0.66	0.63	0.64	0.8	0.09	0.56	-0.17	0.56	0.56	0.61	0.65	0.7	0.23	0.79	0.41		-0.34	0.59	0.09	0.78	0.56
Short Long Term Debt	-0.03	-0.07	0.1	-0.02	-0.03	0.07	-0.05	-0.13	0.34	0.08	0.01	-0.13	0.18	-0.08	0.01	-0.06	-0.29	-0.13	0.14	-0.34		0.18	0.03	0.01	-0.13
Long Term Debt Total	0.78	0.67	0.9	0.7	0.72	0.93	0.59	0.6	0.76	0.88	-0.33	0.46	0.98	0.61	0.82	0.7	-0.36	0.63	0.86	0.59	0.18		0.21	0.71	0.44
Net Invested Capital	0.22	0.24	0.22	0.24	0.28	0.13	0.18	-0.07	0.32	0.07	-0.19	0.44	0.19	-0.21	0.22	0.19	0.16	0.17	0.01	0.09	0.03	0.21		0.12	0.45
Net Working Capital	0.9	0.89	0.67	0.85	0.88	0.79	0.82	0.86	0.33	0.76	-0.42	0.76	0.7	0.81	0.87	0.89	0.27	0.94	0.65	0.78	0.01	0.71	0.12		0.74
Capital Stock	0.77	0.83	0.46	0.76	0.84	0.53	0.71	0.55	0.08	0.48	-0.59	1.0	0.44	0.33	0.71	0.77	0.6	0.84	0.3	0.56	-0.13	0.44	0.45	0.74

Click cells to compare fundamentals

Bio Current Valuation Historical Pattern

Today, most investors in Bio Techne Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Techne's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bio Techne current valuation as a starting point in their analysis.

Bio Techne Current Valuation

Timeline

Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Competition

Predict Bio Techne

Enterprise Value Over Time

In accordance with the recently published financial statements, Bio Techne Corp has a Current Valuation of 12.17 B. This is 15.24% lower than that of the Life Sciences Tools & Services sector and 162.07% higher than that of the Health Care industry. The current valuation for all United States stocks is 26.77% higher than that of the company.

Bio Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Techne's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics of similar companies.

Bio Techne is currently under evaluation in current valuation category among its peers.

Bio Techne ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bio Techne's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bio Techne's managers, analysts, and investors.

Environmental

Governance

Social

Bio Fundamentals

	Return On Equity	0.0729
	Return On Asset	0.0555
	Profit Margin	0.13 %
	Operating Margin	0.18 %
	Current Valuation	12.17 B
	Shares Outstanding	158.89 M
	Shares Owned By Insiders	1.03 %
	Shares Owned By Institutions	99.53 %
	Number Of Shares Shorted	4.05 M
	Price To Earning	74.38 X
	Price To Book	5.75 X
	Price To Sales	10.17 X
	Revenue	1.16 B
	Gross Profit	773.94 M
	EBITDA	310.37 M
	Net Income	168.07 M
	Cash And Equivalents	247.03 M
	Cash Per Share	6.30 X
	Total Debt	419.54 M
	Debt To Equity	0.19 %
	Current Ratio	3.44 X
	Book Value Per Share	13.08 X
	Cash Flow From Operations	298.98 M
	Short Ratio	5.32 X
	Earnings Per Share	0.98 X
	Price To Earnings To Growth	2.76 X
	Target Price	86.8
	Number Of Employees	3.1 K
	Beta	1.28
	Market Capitalization	11.92 B
	Total Asset	2.7 B
	Retained Earnings	1.33 B
	Working Capital	458.04 M
	Current Asset	253.89 M
	Current Liabilities	54.15 M
	Annual Yield	0 %
	Five Year Return	0.56 %
	Net Asset	2.7 B

About Bio Techne Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

V	Visa Class A
GM	General Motors
C	Citigroup
BAC	Bank of America
DD	Dupont De Nemours

When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:

How To Invest In Bio

Details

Is Bio Stock a good investment?

Details

What is Bio Techne's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Bio Techne Piotroski F Score and Bio Techne Altman Z Score analysis.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.32)

Earnings Share

0.98

Revenue Per Share

7.424

Quarterly Revenue Growth

0.045

Return On Assets

0.0555

The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bio Techne Corp Stock Current Valuation

Bio Techne Corp Company Current Valuation Analysis

Enterprise Value

Market Cap + Debt

-

Cash

Current Bio Techne Current Valuation

Bio Current Valuation Driver Correlations

Bio Current Valuation Historical Pattern

Bio Current Valuation Peer Comparison

Bio Techne ESG Sustainability

Bio Fundamentals

About Bio Techne Fundamental Analysis

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY